11 October 2022 | Other

Merck's blood vessel disease drug passes final stage of testing

Merck & Co's $11.5 billion acquisition of pharmaceutical company Acceleron Pharma last year enabled Merck & Co to take advantage of therapy that achieved a major late-stage study goal in patients with advanced blood vessel disorder, Merck said on Monday.

Truist Securities analyst Robin Karnauskas said that in addition to the fact that the data obtained during testing confirm the correctness of the Acceleron deal, trial data also support Merck's promising cardiovascular drug line.

By 2030, Merck's cardiovascular product line is expected to consist of 8 approved drugs and reach a peak in sales of $10 billion, the company said.

Company MarketCheese
Period: 21.04.2026 Expectation: 500 pips
Purchasing Brent crude with $119 in sight
Today at 11:48 AM 13
Period: 14.04.2026 Expectation: 2250 pips
Investing in Tesla stocks on their potential rebound to $375
Today at 11:19 AM 16
Period: 14.04.2026 Expectation: 865 pips
Selling AUDUSD with 0.68300 target as US deadline on Strait of Hormuz approaches
Today at 08:38 AM 12
Period: 21.04.2026 Expectation: 1530 pips
Short-term Bitcoin selloff targets $67,000
Today at 08:35 AM 15
Period: 20.04.2026 Expectation: 1250 pips
Selling EURUSD down to 1.14000
Yesterday at 09:18 AM 26
Gold buy
Period: 13.04.2026 Expectation: 30000 pips
Gold gains momentum to test resistance
Yesterday at 09:15 AM 53
Go to forecasts